Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000550899 | SCV000622224 | pathogenic | Ataxia-telangiectasia syndrome | 2017-06-13 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exons 38-63 of the ATM gene. The 5' boundary is likely confined to intron 37. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion may not result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. While this particular variant has not been reported in the literature, gross deletions and loss-of-function variants in ATM are known to be pathogenic (PMID: 25614872, 23807571). This gross deletion eliminates the last 1,165 amino acid residues of the ATM protein, including the FAT, PI3/4 kinase, and FATC or PIK-related kinase domains, which are crucial for the proper function of the ATM protein (PMID: 23532176, 25460276, 19781682). In addition, a deletion encompassing exons 62-63 and the 3' UTR of ATM has been reported in individuals with ataxia-telangiectasia, and determined to be pathogenic (PMID: 9443866, 25614872). For these reasons, this variant has been classified as Pathogenic. |